by Truveta staff | May 8, 2025 | News
With more than 7 million oncology patient journeys spanning more than 100 cancer types, Truveta is leading a new era in cancer research, delivering an unprecedented breadth of regulatory grade data to support researchers in accelerating oncology therapy adoption and...
by Truveta staff | May 6, 2025 | Culture
This week we gathered with leaders across healthcare, public health, and life sciences at the 3rd annual Truveta Symposium. Truveta Symposium uniquely brings together leaders from life science, public health, and healthcare organizations to collaborate on health...
by Truveta Research | May 6, 2025 | Research, Research Insights
Although a majority of women report intrauterine device (IUD) insertion to be moderately to severely painful, so far in 2025, only 1 in 20 women received pain medication on the day of IUD insertion. The use of pain medication during IUD insertions more than doubled...
by Truveta staff | Apr 15, 2025 | Research, Research Insights
Truveta Research explored the monthly trends in the incidence of syphilis among US adults from January 2017 and October 2024. During the early months of the COVID-19 pandemic, the rate of syphilis incidence (e.g., new infection) increased significantly, reaching a...
by Truveta Research | Apr 3, 2025 | Research, Research Insights
The vaccination rate by age six fluctuated between 2018 and 2021; however, rates have decreased since 2021. The rate in 2021 was 81.9% compared to 80.4% in 2024. This means for every 70 children, roughly one more child received two measles vaccines in 2021 compared to...
